Black Belt Therapeutics Limited

Innovent Biologics (suzhou) Co., Ltd.

Adimab, LLC

Hemanta Baruah

Bianka Prinz

Pascal Merchiers

Beatriz Goyenechea Corzo

Anne Goubier

Kevin Moulder

Josephine Salimu

Simone Filosto

Nina Eissler

Xiaolin Liu

Andy Tsun

Cheng Chen

Junjian Liu

Bingliang Chen

Weifeng Huang

De-Chao Michael Yu

Dechao Michael Yu

Robert Mabry

The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

CD38 modulating antibody agents

CD38 modulating antibody

Multispecific antibody analogs that co-engage at least two different antigens or epitopes, which may also be referred to as targets as used interchangeably throughout, said analogs comprising a common light chain, are provided, as well as methods for their production and use.

Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use

CD38 antibody

The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

The present invention relates to an antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.

Anti-OX40 antibody and use thereof

The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

PD-1 antibodies

Growing community of inventors

Lebanon, NH, United States of America

Hemanta Baruah